Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spartalizumab, mDCF and Radiotherapy in Metastatic Squamous Cell Anal Carcinoma
NCT04894370Phase 2Active, not recruiting
- Sponsor
- CHU de Besançon
- Start
- Jun 2022
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of spartalizumab in anal squamous cell carcinoma (ASCC), sponsored by CHU de Besançon. Started Jun 2022; status: active, not recruiting.
02
Drugs
spartalizumab
03
Conditions
anal squamous cell carcinoma (ASCC)
Beyond the preview
Go deeper on NCT04894370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04894370.